10:52 AM EDT, 03/14/2024 (MT Newswires) -- Keros Therapeutics ( KROS ) said Thursday the Food and Drug Administration has given fast track designation for KER-050 to treat anemia in adults with lower-risk myelodysplastic syndromes.

The company said it will work with the agency on the design of a phase 3 trial to evaluated the drug in lower-risk myelodysplastic syndromes in the first half of this year.

Fast track designation facilitates the development and expedites the review of drugs that show the potential to address unmet medical needs in serious diseases, the company said.

KER-050 is under development to treat low blood cell counts in people with myelodysplastic syndromes and in people with myelofibrosis, the company said.

Price: 66.05, Change: -1.61, Percent Change: -2.38